Geoffrey Banks, Ph.D., founded Nuventra in 2008 and led the company as both its CEO and as a principal consultant for more than 13 years prior to the acquisition of Nuventra by CATO SMS. He has over 20 years of extensive experience in large pharma, biotechnology, and specialty pharma and an established track record of clinical, regulatory, and entrepreneurial success within the pharmaceutical industry.
Dr. Banks received his Ph.D., in protein biochemistry from Washington State University and transitioned to pharmaceutical drug development following a post-doctoral appointment at NIH. The first compound worked on in his pharmaceutical career was HUMIRA® (adalimumab) for the treatment of rheumatoid arthritis and, during his work at Salix Pharmaceuticals, he led the Xifaxan® (rifaximin) clinical program that won FDA approval for the Hepatic Encephalopathy indication.
He brings C-level and drug development expertise to Nuventra from his work as a clinical pharmacology/PK/PD consultant and corporate R&D adviser to over 300 companies that range from venture-backed, start-up biotech companies through large multinational pharmaceutical companies. He has valuable insight into business and R&D operations as well as R&D strategies for pharma/biotech companies with compounds (small molecules and biologics) across all stages of drug development (discovery through IND, early phase through late phase clinical development, and marketing authorizations [NDA/BLA/MAA/ANDA] through post-approval commitments).
Dr. Banks is also the co-founder of a virtual drug development company (1st Order Pharmaceuticals, Inc.) that acquired a small molecule potassium channel opener for Kv7 (KCNQ) ion channels for central nervous system hyperexcitability-related disorders in neurology and pain. In 2017, 1st Order Pharmaceuticals divested the asset as announced “Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy.”